Proteomic Analysis of Cervicovaginal Fluid for Diagnostic Endometriosis Biomarker Discovery
PROTEOMICS – Clinical Applications · 2026
DOI: 10.1002/prca.70044 ↗At a glance
Journal article in PROTEOMICS – Clinical Applications, 2026. Written by Emily S J Paterson and 7 co-authors. Institution: Department of Surgery and Anaesthesia, University of Otago, Ōtākou Whakaihu Waka, Wellington, Aotearoa, New Zealand. Major MEDLINE topics: Endometriosis, Proteomics, Vagina, Body Fluids. Cited 1 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
Abstract (original language)
Purpose
Endometriosis is a prevalent inflammatory condition characterised by the presence of endometrial‐like tissue outside the uterus and is associated with significant challenges, including diagnostic delays and continued reliance on laparoscopy. Although extensive research has investigated potential biomarkers in various biofluids, none have been validated for clinical use. Experimental design This pilot study explored the proteome of cervicovaginal fluid to identify biomarkers of endometriosis. SWATH‐MS was performed over two experiments on cervicovaginal fluid sampled via a low vaginal swab, from people with ( n = 20) and without ( n = 19) surgically confirmed endometriosis. STRING, OPLS‐DA modelling and ingenuity pathway analysis were used to interrogate the data. ELISA was performed validate SWATH‐MS findings.
Results
There were 29 proteins in experiment one and 47 proteins in experiment two identified as differentially abundant between cases and controls. No proteins were identified as differentially abundant in both experiments. Legumain (LGMN) measured via ELISA was significantly increased in the cervicovaginal fluid of people with endometriosis. Conclusions and clinical relevance Cervicovaginal fluid proteins sampled via vaginal swab may have limited biomarker potential for endometriosis. A larger and more diverse cohort would be required to confirm the promise of cervicovaginal fluid LGMN as a candidate biomarker of endometriosis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Surgery and Anaesthesia, University of Otago, Ōtākou Whakaihu Waka, Wellington, Aotearoa, New Zealand.
- Department of Obstetrics, Gynaecology and Women's Health, University of Otago, Ōtākou Whakaihu Waka, Wellington, Aotearoa, New Zealand.
- Department of Obstetrics and Gynaecology, Wellington Hospital, Te Whatu Ora - Capital, Coast and Hutt Valley, Wellington, Aotearoa, New Zealand.
- Department of Biochemistry, University of Otago, Ōtākou Whakaihu Waka, Dunedin, Aotearoa, New Zealand.
- Department of Anatomy, University of Otago, Ōtākou Whakaihu Waka, Dunedin, Aotearoa, New Zealand.
ORCID profiles: Emily S J Paterson
Funding
- Royal Australian and New Zealand College of Obstetricians and Gynaecologists
Cite
APA
Paterson, E. S. J., Scheck, S., Kleffmann, T., Gill, R., Bedford, N., McDowell, S., Girling, J. E., & Henry, C. E. (2026). Proteomic Analysis of Cervicovaginal Fluid for Diagnostic Endometriosis Biomarker Discovery. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.70044
Vancouver
Paterson ESJ, Scheck S, Kleffmann T, Gill R, Bedford N, McDowell S, et al. Proteomic Analysis of Cervicovaginal Fluid for Diagnostic Endometriosis Biomarker Discovery. PROTEOMICS – Clinical Applications. 2026. doi:10.1002/prca.70044
BibTeX
@article{Paterson2026,
author = {Paterson, Emily S J and Scheck, Simon and Kleffmann, Torsten and Gill, Roopi and Bedford, Nicholas and McDowell, Simon and Girling, Jane E and Henry, Claire E},
title = {Proteomic Analysis of Cervicovaginal Fluid for Diagnostic Endometriosis Biomarker Discovery},
journal = {PROTEOMICS – Clinical Applications},
year = {2026},
doi = {10.1002/prca.70044}
}
EUVIMED